3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 3
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
OTHER
6
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
34
Gastrointestinal
19
Thoracic
10
Tumor-Agnostic
5
Gynecologic
5
Genitourinary
4
Other solid neoplasm
3
CNS
3
Sarcoma
2
Dermatologic
2
Head & Neck
1
Conditions
Breast Neoplasms
3
Brain Neoplasms
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
123
Radiotherapy
47
Bevacizumab
46
Lomustine
25
Radiation
20
Nivolumab
17
Irinotecan
16
Carboplatin
16
Cyclophosphamide
14
Granulocyte-Macrophage Colony-Stimulating Factor
13
pembrolizumab
11
dabrafenib
10
Trastuzumab
10
Surgical Procedures, Operative
10
Capecitabine
10
paclitaxel-Angiopep-2 conjugate
8
TIC10 compound
8
Paclitaxel
8
Gemcitabine
8
Carmustine
8
trametinib
7
Topotecan
7
IL13-PE38
7
Everolimus
7
Drug Therapy
7
Aminolevulinic Acid
7
AZD 6244
7
3-Iodobenzylguanidine
7
fludarabine
6
enzastaurin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
trastuzumab deruxtecan
×
CNS
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled
NCT04739761
2026-05-12
DESTINY-B12
AstraZeneca
Phase 3
Active not recruiting
506 enrolled
27 charts
NCT04538742
2025-12-08
DB-07
AstraZeneca
Phase 1/2
Active not recruiting
245 enrolled